文献速递自身炎症与 IgG4 相关病

NLRP3相关自身炎症性疾病的耳科表现:聚焦阿那白滞素治疗反应

Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

三个先证者听力对阿那白滞素显示应答,而阿那白滞素开始时听阈差于60 dB及脑MRI耳蜗增强可能与听力预后和治疗反应不佳相关。

要点

  • NLRP3变异相关CAPS/DFNA34中,部分感音神经性耳聋对阿那白滞素治疗有应答。
  • 阿那白滞素开始时听阈差于60 dB及脑MRI耳蜗增强可能与听力预后和应答不佳相关。
  • NLRP3基因型、诊断时听力状态及耳蜗影像学表现可能作为阿那白滞素治疗后听力预后的生物标志物。

核心结论

  • NLRP3基因型、诊断时听力状态和耳蜗影像学发现可能作为阿那白滞素治疗后听力预后的生物标志物,并可能作为调整治疗剂量的敏感参数。

主要发现

  • 队列中94.1%存在NLRP3变异,新发 occurrence 为84.6%。
  • 鉴定出全球第二个DFNA34家系,携带新型NLRP3变异并有体外分析支持。
  • 三个先证者听力状态较自然病程有显著改善,显示对阿那白滞素应答,其中一人曾有重度感音神经性耳聋。
  • 阿那白滞素开始时听阈差于60 dB及脑MRI耳蜗增强似乎与较差的听力学预后和对阿那白滞素治疗反应性相关,尽管全身症状和炎症标志物稳定。

关键数值与推荐

  • 阿那白滞素开始时听阈差于60 dB及脑MRI耳蜗增强与较差的听力学预后和应答相关。
  • NLRP3基因型、诊断时听力状态和耳蜗影像学发现被提议作为阿那白滞素治疗后听力预后的生物标志物。

临床怎么用

  • 对于NLRP3相关自身炎症性疾病患者,应评估诊断时听力状态和脑MRI耳蜗增强,以预判阿那白滞素治疗后的听力预后。
  • NLRP3基因型、听力和耳蜗影像学可能用于调整阿那白滞素治疗剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Gradually progressive sensorineural hearing loss (SNHL) is a prevalent sensory defect. It is generally untreatable, making rehabilitation by hearing aid or cochlear implantation the only option. However, SNHL as one of the symptoms of the hereditary autoinflammatory systemic disease cryopyrin-associated periodic syndrome, or as the only symptom of the cochlea-specific form (DFNA34), was suggested to respond to IL-1 antagonist (anakinra) therapy, which ameliorates NLRP3 variants-induced over-secretion of IL-1β. We analysed genotypic and phenotypic spectrum of cryopyrin-associated periodic syndrome or DFNA34, specifically focusing on the responsiveness of SNHL to anakinra. METHODS: Seventeen families diagnosed with either cryopyrin-associated periodic syndrome or DFNA34 were recruited. Genotyping and phenotyping including audiogram, MRI findings, and in vitro IL-1β assay were performed. RESULTS: Our cohort had an etiologic homogeneity of 94.1% to NLRP3 variants and a high de novo occurrence (84.6%). We identified the second DNFA34 pedigree worldwide with a novel NLRP3 variant supported by in vitro analysis. Significant improvement of hearing status against the natural course, showing response to anakinra, was identified in three probands, one of whom used to have severe SNHL. Hearing threshold worse than 60 dB at the start of anakinra and cochlear enhancement on brain MRI seemed to be related with poor audiologic prognosis and responsiveness to anakinra therapy despite stabilized systemic symptoms and inflammatory markers. CONCLUSION: We propose a constellation of biomarkers comprising NLRP3 genotypes, hearing status at diagnosis, and cochlear radiological findings as prognostic factors of hearing status after anakinra treatment and possibly as sensitive parameters for treatment dosage adjustment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kim BJ, Kim YH, Lee S, et al. Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to anakinra. Rheumatology (Oxford). 2021. PMID: 33020839. doi:10.1093/rheumatology/keaa511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。